Karyopharm Therapeutics Inc. (KPTI) vs Moleculin Biotech, Inc. (MBRX)
- Karyopharm Therapeutics Inc. KPTI 0.39 +11.43%
- Moleculin Biotech, Inc. MBRX 0.28 −24.32%
Karyopharm Therapeutics Inc. and Moleculin Biotech, Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and Moleculin Biotech, Inc. are of similar size ($8.0M and $7.6M). Karyopharm Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.0×. Moleculin Biotech, Inc. has the higher net margin (0.00% vs −153.3%) and the lower return on invested capital (−417.3% vs 0.00%). Across the 13 metrics below, Moleculin Biotech, Inc. leads on 7 and Karyopharm Therapeutics Inc. on 6.
Valuation
Profitability
| Metric | KPTI | MBRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 95.89% | 0.00% | 65.16% |
| Operating margin | (56.17%) | 0.00% | 0.00% |
| Net margin | (153.28%) | 0.00% | 0.00% |
| Free cash flow margin | (44.57%) | 0.00% | 0.00% |
| Return on equity | 78.98% | (1,471.05%) | (56.36%) |
| Return on assets | (207.90%) | (152.41%) | (48.04%) |
| Return on invested capital | 0.00% | (417.27%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack